AI Article Synopsis
- Uninterrupted anticoagulation for atrial fibrillation (AF) has been a standard practice since early research, aimed at preventing strokes regardless of how long AF lasts.
- However, this approach carries risks and may not be suitable for everyone with a history of AF.
- The REACT-AF trial is being introduced to investigate a more targeted method of anticoagulation, known as "pill in the pocket" approach, which could be more beneficial for certain patients.
Article Abstract
Uninterrupted anticoagulation for atrial fibrillation (AF), regardless of AF burden, is deeply rooted in practice since the early anticoagulation trials. However, uninterrupted anticoagulation is not without risks, and may not be beneficial for allcomers with a history of AF. Indeed, contemporary data that support a critical duration threshold of AF that benefits from anticoagulation, and a temporal association between stroke and multihour AF episodes, compel the study of a more targeted approach to AF anticoagulation. In this review, we discuss data that support further investigation of "pill in the pocket" anticoagulation for AF, and introduce the pivotal Rhythm Evaluation for Anticoagulation Therapy for Atrial Fibrillation (REACT-AF) trial that will robustly evaluate this strategy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/jce.15866 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!